Jan. 27, 2026 — A new national study reveals a stark disconnect between Americans’ desire for preventive cardiac screening and the care they can access. Despite heart disease remaining the leading cause of death in the U.S., the study finds that only 28% of Americans who have had a heart ultrasound were offered it as a preventive measure, and just 30% say they have convenient access to advanced heart screening close to home.

Jan. 26, 2026 — AISAP,  a provider of AI point-of-care diagnostics, has published a new clinical study in the peer-reviewed journal Frontiers in Digital Health. The research provides clinical evidence that AISAP’s deep learning model can accurately detect significant valvular disease and ventricular dysfunction using only a single, focused ultrasound view, even when the images are acquired by non-cardiologists using handheld devices.

Jan. 20, 2026 — Abbott has received CE Mark in Europe for the TactiFlex Duo Ablation Catheter, Sensor Enabled to treat patients with atrial fibrillation (AFib). Following the new approval, the first successful commercial cases using TactiFlex Duo in the European Union were completed this week.

Jan. 20, 2026 — Polarean, a commercial-stage medical imaging company advancing functional MRI of the lungs, has expanded its Xenon MRI platform into cardiopulmonary pharma-sponsored drug development through a multi-center U.S. study in PH-ILD.

Jan. 15, 2026 — Boston Scientific Corp. and Penumbra, Inc. have entered into a definitive agreement under which Boston Scientific will acquire Penumbra in a cash and stock transaction.ⁱ